29
https://pubmed.ncbi.nlm.nih.gov/38115904
Two cases of people living with HIV who received lenvatinib for recurrent hepatocellular carcinoma showed low tolerability to the treatment, highlighting the need for further data to determine the position of lenvatinib in this setting.